However, there is a notable paucity of studies exploring the efficacy of SGLT2 inhibitors in other autoimmune disorders, such as RA, MS and Sjögren’s syndrome, future clinical studies are warranted in these areas. This evidence concerns the gene SLC5A2 and rheumatoid arthritis.